Healthcare provider profile · identity verified

Martha Hartwig Ripon, MD

Internal Medicine · MINNEAPOLIS, MN · NPI 1154384675

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	188	52
Gabapentin	Gabapentin	170	45
Levothyroxine Sodium	Levothyroxine Sodium	139	32
Furosemide	Furosemide	138	51
Eliquis	Apixaban	116	34
Pantoprazole Sodium	Pantoprazole Sodium	109	24
Amlodipine Besylate	Amlodipine Besylate	104	35
Metoprolol Succinate	Metoprolol Succinate	103	30
Losartan Potassium	Losartan Potassium	100	37
Rosuvastatin Calcium	Rosuvastatin Calcium	93	22
Mirtazapine	Mirtazapine	83	18
Warfarin Sodium	Warfarin Sodium	82	17
Simvastatin	Simvastatin	78	14
Metoprolol Tartrate	Metoprolol Tartrate	77	25
Lisinopril	Lisinopril	72	23
Clopidogrel	Clopidogrel Bisulfate	69	18
Omeprazole	Omeprazole	68	23
Potassium Chloride	Potassium Chloride	67	25
Tamsulosin Hcl	Tamsulosin Hcl	60	18
Trazodone Hcl	Trazodone Hcl	58	20
Carbidopa-Levodopa	Carbidopa/Levodopa	53	suppressed
Sertraline Hcl	Sertraline Hcl	52	13
Carvedilol	Carvedilol	50	11
Torsemide	Torsemide	49	suppressed
Famotidine	Famotidine	45	15
Duloxetine Hcl	Duloxetine Hcl	41	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	41	suppressed
Fluticasone Propionate	Fluticasone Propionate	38	18
Fluoxetine Hcl	Fluoxetine Hcl	37	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	37	suppressed
Diclofenac Sodium	Diclofenac Sodium	32	12
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	31	suppressed
Memantine Hcl	Memantine Hcl	26	suppressed
Allopurinol	Allopurinol	25	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	25	suppressed
Donepezil Hcl	Donepezil Hcl	24	11
Doxycycline Hyclate	Doxycycline Hyclate	24	14
Atenolol	Atenolol	23	suppressed
Midodrine Hcl	Midodrine Hcl	23	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	22	suppressed
Metformin Hcl	Metformin Hcl	21	12
Oxycodone Hcl	Oxycodone Hcl	21	21
Sucralfate	Sucralfate	21	suppressed
Januvia	Sitagliptin Phosphate	20	suppressed
Amiodarone Hcl	Amiodarone Hcl	18	suppressed
Buspirone Hcl	Buspirone Hcl	18	suppressed
Prednisone	Prednisone	18	13
Albuterol Sulfate Hfa	Albuterol Sulfate	17	16
Clonidine Hcl	Clonidine Hcl	17	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	17	suppressed
Finasteride	Finasteride	17	suppressed
Timolol Maleate	Timolol Maleate	17	suppressed
Bumetanide	Bumetanide	16	suppressed
Jantoven	Warfarin Sodium	16	suppressed
Latanoprost	Latanoprost	16	suppressed
Methocarbamol	Methocarbamol	16	12
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Valproic Acid	Valproic Acid	16	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	15	suppressed
Cephalexin	Cephalexin	15	11
Citalopram Hbr	Citalopram Hydrobromide	15	suppressed
Metolazone	Metolazone	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Benazepril Hcl	Benazepril Hcl	14	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	14	suppressed
Olanzapine	Olanzapine	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Baclofen	Baclofen	13	suppressed
Divalproex Sodium	Divalproex Sodium	13	suppressed
Insulin Aspart Flexpen	Insulin Aspart	13	suppressed
Montelukast Sodium	Montelukast Sodium	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	12	suppressed
Loperamide	Loperamide Hcl	12	suppressed
Metronidazole	Metronidazole	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Diltiazem 12hr Er	Diltiazem Hcl	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error